Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Unknown status
National Cancer Institute (NCI)
Phase 2
2018-09-18
This phase II trial studies how well enasidenib and azacitidine work in treating patients
with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not
respond to treatment (refractory). Enasidenib and azacitidine may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth.
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Unknown status
M.D. Anderson Cancer Center
Phase 2
2018-09-18
This phase II trial studies how well enasidenib and azacitidine work in treating patients
with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not
respond to treatment (refractory). Enasidenib and azacitidine may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth.
Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutation After Donor Stem Cell Transplant
Recruiting
National Cancer Institute (NCI)
Phase 1
2019-07-11
This phase I trial studies the side effects of using enasidenib as maintenance therapy in
treating patients with acute myeloid leukemia with IDH2 mutation following donor stem cell
transplant. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
